Regulatory Updates, In Brief
Executive Summary
FDA won't review Merck Serono's oral cladribine NDA: FDA refused to file the NDA for Merck Serono's oral multiple sclerosis drug cladribine, the firm announced Nov. 30. The application was filed in September by the company's U.S. subsidiary EMD Serono (1"The Pink Sheet" DAILY, Sept. 30, 2009). FDA granted the cladribine NDA fast track status based on the need for an oral therapy in the subset of MS patients with relapsing disease. Though Merck Serono was first to submit an NDA for an oral therapy for relapsing MS, it has not been the odds-on favorite for first approval (2IN VIVO, November 2009). At Windhover's FDA/CMS Summit Dec. 3, FDA Office of New Drugs Director John Jenkins spoke generally of the agency's refuse-to-file actions, noting that if industry wants FDA to meet PDUFA review dates, complete applications must be submitted (3The IN VIVO Blog, Dec. 3, 2009)
You may also be interested in...
Merck Serono Submits Oral Cladribine But That Doesn't End The Oral MS Race
Merck Serono's NDA filing will not prohibit a possible priority review for Novartis' oral FTY720, which had Phase III data released the same day; both applications face close scrutiny with less than ideal clinical trial packages.
Expanded NIH Stem Cell Support Means Novel Drug Development Tools
A new generation of specialized drug development tools based on human embryonic stem cells - and maybe down the road new regenerative therapies - got a boost with the release of the Obama administration's hESC research guidelines July 6
Seroquel XR Might Get Second Line For Depression, Anxiety Despite Safety Worry
A second-line indication for AstraZeneca's Seroquel XR (quetiapine) in major depressive disorder and generalized anxiety disorder remains possible following a unanimous FDA advisory committee vote that the drug is not "acceptably safe" for the monotherapy claims in MDD and GAD that AstraZeneca had been seeking